MKA
REGN icon

M. Kulyk & Associates’s Regeneron Pharmaceuticals REGN Stock Holding History

M. Kulyk & Associates’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.5M Buy
14,895
+91
+0.6% +$69.7K 2.15% 13
2025
Q4 		$11.4M Buy
14,804
+431
+3% +$293K 2.18% 13
2025
Q3 		$8.08M Buy
14,373
+10,368
+259% +$5.86M 1.64% 19
2025
Q2 		$2.1M Buy
4,005
+1,318
+49% +$736K 0.46% 51
2025
Q1 		$1.7M Buy
2,687
+528
+24% +$363K 0.39% 53
2024
Q4 		$1.54M Buy
+2,159
New +$1.81M 0.33% 52

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

M. Kulyk & Associates's REGN Position: Q1 2026 in Review

M. Kulyk & Associates increased its Regeneron Pharmaceuticals (REGN) stake by 0.61% in Q1 2026, buying an estimated $69.7K and bringing the position to 14,895 shares worth $11.5M. The position accounts for 2.15% of the portfolio, ranked #13.

M. Kulyk & Associates first reported a position in REGN in Q4 2024 and has held it in 6 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • M. Kulyk & Associates held 14,895 shares of Regeneron Pharmaceuticals worth $11.5M as of Q1 2026.
  • M. Kulyk & Associates bought 91 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $69.7K.
  • Regeneron Pharmaceuticals made up 2.15% of M. Kulyk & Associates's portfolio in Q1 2026, its #13 holding.
  • M. Kulyk & Associates first reported a position in Regeneron Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on M. Kulyk & Associates's 13F filing for Q1 2026, filed 6 May 2026.